Coherus BioSciences Ownership

CHRS Stock  USD 1.03  0.08  8.42%   
Coherus BioSciences holds a total of 115.9 Million outstanding shares. Over half of Coherus BioSciences' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Coherus BioSciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Coherus Stock please use our How to Invest in Coherus BioSciences guide.

Coherus Stock Ownership Analysis

About 58.0% of the company shares are held by institutions such as insurance companies. The company last dividend was issued on the June 26, 1995. Coherus BioSciences had 2:1 split on the December 8, 1992. Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. Coherus Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 368 people. For more info on Coherus BioSciences please contact Dennis Lanfear at 650 649 3530 or go to https://www.coherus.com.

Coherus BioSciences Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Coherus BioSciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Coherus BioSciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Coherus BioSciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Paul Reider six days ago
Disposition of 2073 shares by Paul Reider of Coherus BioSciences at 1.61 subject to Rule 16b-3
 
Paul Reider over two weeks ago
Acquisition by Paul Reider of 160000 shares of Coherus BioSciences at 3.14 subject to Rule 16b-3
 
Dennis Lanfear over two months ago
Disposition of 11810 shares by Dennis Lanfear of Coherus BioSciences at 1. subject to Rule 16b-3
 
Vladimir Vexler over two months ago
Disposition of 5437 shares by Vladimir Vexler of Coherus BioSciences at 9.87 subject to Rule 16b-3
 
Dennis Lanfear over two months ago
Acquisition by Dennis Lanfear of 575000 shares of Coherus BioSciences at 1.47 subject to Rule 16b-3
 
Bryan Mcmichael over two months ago
Disposition of 1711 shares by Bryan Mcmichael of Coherus BioSciences at 1.57 subject to Rule 16b-3
 
Paul Reider over two months ago
Disposition of 2277 shares by Paul Reider of Coherus BioSciences at 1.66 subject to Rule 16b-3
 
Paul Reider over two months ago
Acquisition by Paul Reider of 160000 shares of Coherus BioSciences at 1.66 subject to Rule 16b-3
 
Paul Reider over three months ago
Disposition of 2073 shares by Paul Reider of Coherus BioSciences at 1.61 subject to Rule 16b-3
 
Newcomer Lee Nisley over six months ago
Acquisition by Newcomer Lee Nisley of 54000 shares of Coherus BioSciences at 12.44 subject to Rule 16b-3
 
Paul Reider over six months ago
Acquisition by Paul Reider of 40000 shares of Coherus BioSciences at 2.41 subject to Rule 16b-3
 
Wahlstrom Mats over six months ago
Acquisition by Wahlstrom Mats of 29994 shares of Coherus BioSciences at 2.0838 subject to Rule 16b-3

Coherus BioSciences Outstanding Bonds

Coherus BioSciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Coherus BioSciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Coherus bonds can be classified according to their maturity, which is the date when Coherus BioSciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Coherus Stock Analysis

When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.